Previous Article | Next Article ![]()
Journal of Virology, March 2008, p. 2590-2593, Vol. 82, No. 5
0022-538X/08/$08.00+0 doi:10.1128/JVI.01956-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

INSERM, U649, Nantes F-44000, France,1 EFS des Pays de la Loire, Nantes F-4400, France,2 Istituto Scientifico H. San Raffaele, Gene Therapy Program, Milano, Italy,3 University of Modena and Reggio Emilia, Department of Biomedical Sciences, Modena, Italy,4 INSERM, U758, Lyon F-69007, France5
Received 6 September 2007/ Accepted 12 December 2007
|
|
|---|
|
|
|---|
Validation of the minimal 55-bp p5 element using a rAAV plasmid-based assay. A first study was conducted to determine if the minimal 55-bp p5 element, identified as an efficient replication origin (3), was also able to increase RMSSI of rAAV plasmid as previously documented for the entire p5 region. To answer this question, we used the procedure that was previously employed by other investigators (7, 10, 11), consisting of the analysis of stable cell clones isolated from HeLa cells transfected with the rAAV plasmid containing different versions of the p5 element inserted between the ITRs (Fig. 1). The wild-type (wt) 163-bp p5 region covers the entire p5 promoter from the major late transcription factor binding region to position 353, downstream from the HP region. The minimal 55-bp p5 region (p5D10) includes only the four elements previously described as essential for in vivo and in vitro replication (Fig. 1) (3). Since our previous analysis indicated a critical role of the TATA box for in vivo replication, two additional replication-defective p5 elements containing either a mutation (p5mTATA) or a deletion (p5D12) of this binding site were inserted into the rAAV vector plasmid. Each rAAV plasmid was cotransfected into HeLa cells together with a plasmid expressing Rep under the control of doxycycline-inducible promoter (pBGTetOCMVRepTS) (12). Two weeks after transfection and culture in the presence of doxycycline, green fluorescent protein (GFP)-positive cells were sorted by a fluorescence-activated cell sorter and cloned by limiting dilution. After expansion, each clone was analyzed for the presence of the gfp sequence by PCR and visualization of GFP expression. As expected, only a portion of the selected clones had integrated the gfp sequence (Table 1), and all the clones containing this gene also expressed the protein, although at different levels (data not shown). In each of these GFP-stable cell clones, RMSSI was detected by Southern blot analysis performed for EcoRI-digested DNA by using, first, an AAVS1 probe to detect rearrangements of this chromosomal region and then, after dehybridization of the membrane, a gfp probe to detect vector-containing bands (Fig. 2). Site-specific integration of the rAAV vector plasmid was defined by the colocalization of the gfp and AAVS-1 bands, as in previous studies of RMSSI. As expected from previous studies, the presence of the wt p5 element significantly increased site-specific integration of the rAAV plasmid compared to results with the pAAV-GFP vector (Table 1). Insertion of the minimal p5D10 element also had a positive effect on RMSSI, similar to that observed for the entire p5 region. In this context, the use of long or short replication-defective p5 elements (p5mTATA and p5D12, respectively) also resulted in an increase of RMSSI, although at a level that was apparently lower than that observed with their respective wt counterparts. Altogether, the results of this plasmid-based assay indicate that the minimal 55-bp region can increase RMSSI of the rAAV plasmid to a level similar to that observed with the wt p5 region and that replication of this element is not strictly required to exert this activity.
![]() View larger version (18K): [in a new window] |
FIG. 1. Schematic view of the pAAV-GFP plasmids containing different versions of p5. The star indicates the presence of a mutated TATA box, and HP indicates the position of the putative HP (3). Positions refer to the wt AAV-2 genome (GenBank no. NC_001401). The control pAAV-GFP plasmid contains a nonrelevant 150-bp region instead of the p5 element.
|
|
View this table: [in a new window] |
TABLE 1. Analysis of HeLa cell clones transfected with AAV-GFP plasmids
|
![]() View larger version (27K): [in a new window] |
FIG. 2. Representative Southern blot analysis of RMSSI in stably transfected HeLa cells clones. HeLa cells (He) were cotransfected with each pAAV-GFP plasmid (Fig. 1) and with a second construct encoding Rep78 under the control of a doxycycline-inducible promoter (pBGTetOCMVRepTS) (12). Whole genomic DNA extracted from of each cell clone was digested by EcoRI and analyzed by Southern blotting using an AAVS1 probe and, after dehybridization, a gfp probe. Genomic DNA from HA-16 cells and the pAAV-GFP plasmid (GFP) served as positive controls for AAVS1 disruption and gfp probe hybridization, respectively. The black arrow indicates the expected EcoRI restriction fragment containing the AAVS1 sequence. The white arrows indicate AAVS1-disrupted bands that colocalize with gfp-containing bands.
|
![]() View larger version (18K): [in a new window] |
FIG. 3. Quantification of RMSSI in transduced HepaRG cells. (A) Human chromosome 19 region (GenBank accession no. AC010327) and position of primers pAAVS1 (5'-TCAGAGGACATCACGTG-3') and pITR (5'-TTAACTACAAGGAACCCCTA-3') used for the amplification of AAVS1-AAV junctions by quantitative PCR. D and A indicate the positions of the donor (5'-TGTTGCTGCCCAAGGATGCT-FL; TIB Molbiol) and acceptor (5'-LC Red640-TTTCCGGAGCACTTCCTTCTCG-p; TIB Molbiol) probes, respectively. The number of integrated AAV copies in the AAVS1 locus was measured by using as a standard different copies of the pAAVS1-ITR control plasmid that carries an artificial AAVS1-chromosome 19 junction fragment (5, 6) and was further calibrated by using genomic DNA extracted from HA-16 cells that contain the wt AAV-2 genome integrated into the AAVS1 site in a head-to-tail configuration (2). Results are expressed as the percentage of AAVS1-ITR junctions found in each sample relative to the number of junctions found using equivalent amounts of HA-16 cells. (B) Differentiated HepaRG cells were transduced with AAV-GFP or AAVp5D10-GFP in the presence or in the absence of a gutless adenovirus encoding Rep78 under the control of a doxycycline-inducible promoter (12). Alternatively, the cells were infected with wt AAV-2 particles (multiplicity of infection, 4,000 physical particles/cell and 20 infectious particles/cell for rAAV and adenoviral vectors, respectively). The percentage of RMSSI was measured for HepaRG cells 5 days after transduction. CTRL, genomic DNA from nontransduced HepaRG cells. (C) HeLa cells were transfected with the Rep-expressing plasmid (pBGTetOCMVRepTS) and then infected with rAAV. Alternatively, the cells were infected with wt AAV2 particles. Both infections were performed at a multiplicity of infection of 4,000 particles/cell. RMSSI was measured by quantitative PCR 3 days after infection and culture in the presence of doxycycline.
|
Altogether, this study documents for the first time the effect of the p5 element in the context of a viral infection. We show that insertion of the p5 region, in either its wt or its minimal version, cannot significantly increase RMSSI of a rAAV vector during infection of proliferating or quiescent human pseudo-primary cells. This result contrasts with the effect previously observed in this and other studies analyzing RMSSI of p5-containing rAAV plasmids after transfection into individual cell clones. This differential effect may depend upon the rAAV substrate introduced into the cells (i.e., a plasmid versus a linear molecule) or the selection procedure performed to obtain individual cell clones. Further studies should be conducted to determine whether, likewise, insertion of the p5 element is dispensable for enhancing RMSSI of rAAV vectors in vivo.
This work was supported by the Association Française contre les Myopathies (AFM), the Association Nantaise de Thérapie Génique (ANTG), the Fondation pour la Thérapie Génique en Pays de la Loire, and the European Commission (contract FP6-019038, Magselectofection).
Published ahead of print on 19 December 2007. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»